Patents by Inventor Katsuyuki Mitomo
Katsuyuki Mitomo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190225986Abstract: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.Type: ApplicationFiled: November 30, 2018Publication date: July 25, 2019Inventors: Katsuyuki Mitomo, Makoto Inoue, Hitoshi Iwasaki, Mamoru Hasegawa, Eric W. Alton, Uta Griesenbach
-
Patent number: 10030071Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.Type: GrantFiled: September 5, 2014Date of Patent: July 24, 2018Assignees: UNIVERSITY OF MIYAZAKI, FUJITA HEALTH UNIVERSITY, PERSEUS PROTEOMICS INC.Inventors: Kazuhiro Morishita, Kazuko Kaneda, Yoshikazu Kurosawa, Gene Kurosawa, Katsuyuki Mitomo, Katsushi Kouda, Yoshinori Ukai
-
Patent number: 10017784Abstract: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.Type: GrantFiled: November 17, 2014Date of Patent: July 10, 2018Assignee: ID PHARMA CO., LTD.Inventors: Katsuyuki Mitomo, Makoto Inoue, Hitoshi Iwasaki, Mamoru Hasegawa, Eric W. Alton, Uta Griesenbach
-
Patent number: 9764041Abstract: It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.Type: GrantFiled: April 4, 2012Date of Patent: September 19, 2017Assignee: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Katsuyuki Mitomo, Katsushi Kouda, Fumiko Nomura, Yoko Kayukawa, Tadashi Matsuura
-
Patent number: 9644028Abstract: The present invention provides an anti-CDH3 humanized antibody having lower immunogenicity, and an anti-CDH3 humanized antibody drug conjugate having the aforementioned anti-CDH3 humanized antibody. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody having complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No.Type: GrantFiled: February 14, 2014Date of Patent: May 9, 2017Assignee: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Katsuyuki Mitomo, Katsushi Kouda, Fumiko Nomura, Yoko Kayukawa, Tadashi Matsuura
-
Patent number: 9598496Abstract: An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).Type: GrantFiled: May 7, 2012Date of Patent: March 21, 2017Assignees: PERSEUS PROTEOMICS INC., UNIVERSITY OF MIYAZAKIInventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Patent number: 9593165Abstract: The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.Type: GrantFiled: November 8, 2013Date of Patent: March 14, 2017Assignees: UNIVERSITY OF MIYAZAKI, PERSEUS PROTEOMICS INC.Inventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Publication number: 20160281109Abstract: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.Type: ApplicationFiled: June 10, 2016Publication date: September 29, 2016Inventors: Katsuyuki Mitomo, Makoto Inoue, Hitoshi Iwasaki, Mamoru Hasegawa, Eric W. Alton, Uta Griesenbach
-
Publication number: 20160200799Abstract: It is an object of the present invention to provide a novel antibody having a high binding activity and a high neutralizing activity on influenza viruses. The present invention provides an antibody, which neutralizes H1 influenza virus and/or H5 influenza virus, wherein the antibody has a heavy chain variable region having CDRs consisting of a defined heavy chain first complementarity-determining region (VH CDR1), a defined heavy chain second complementarity-determining region (VH CDR2) and a defined heavy chain third complementarity-determining region (VH CDR3), and a light chain variable region having CDRs consisting of a defined light chain second complementarity-determining region (VL CDR2) and a defined light chain third complementarity-determining region (VL CDR3).Type: ApplicationFiled: August 20, 2014Publication date: July 14, 2016Applicants: FUJITA HEALTH UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, PERSEUS PROTEOMICS INC.Inventors: Yoshikazu KUROSAWA, Nobuko OSHIMA, Yoshinobu OKUNO, Katsuyuki MITOMO, Katsushi KOUDA
-
Publication number: 20160194400Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.Type: ApplicationFiled: September 5, 2014Publication date: July 7, 2016Applicants: UNIVERSITY OF MIYAZAKI, FUJITA HEALTH UNIVERSITY, PERSEUS PROTEOMICS INC.Inventors: Kazuhiro MORISHITA, Kazuko KANEDA, Yoshikazu KUROSAWA, Gene KUROSAWA, Katsuyuki MITOMO, Katsushi KOUDA, Yoshinori UKAI
-
Publication number: 20160152703Abstract: It is an object of the present invention to produce an anti-CDH3 humanized antibody having lower immunogenicity, and to provide an anti-CDH3 humanized antibody drug conjugate comprising the aforementioned anti-CDH3 humanized antibody that more efficiently kills cancer cells expressing CDH3. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody which comprises complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No.Type: ApplicationFiled: February 14, 2014Publication date: June 2, 2016Applicant: PERSEUS PROTEOMICS INC.Inventors: Keisuke ISHII, Katsuyuki MITOMO, Katsushi KOUDA, Fumiko NOMURA, Yoko KAYUKAWA, Tadashi MATSUURA
-
Patent number: 9328160Abstract: It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.Type: GrantFiled: October 28, 2011Date of Patent: May 3, 2016Assignee: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Keiko Katsumi, Tadashi Matsuura, Yukio Sudo, Katsuyuki Mitomo, Katsushi Kouda
-
Publication number: 20160058883Abstract: It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.Type: ApplicationFiled: April 4, 2012Publication date: March 3, 2016Applicant: PERSEUS PROTEOMICS INC.Inventors: Keisuke ISHII, Katsuyuki MITOMO, Katsushi KOUDA, Fumiko NOMURA, Yoko KAYUKAWA, Tadashi MATSUURA
-
Publication number: 20150291697Abstract: The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.Type: ApplicationFiled: November 8, 2013Publication date: October 15, 2015Applicants: PERSEUS PROTEOMICS INC., UNIVERSITY OF MIYAZAKIInventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Patent number: 9127061Abstract: It is an object to provide a recombinant antibody that is an anti-CDH3 antibody having cytotoxicity on CDH3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention provides a recombinant antibody which specifically reacts with an epitope existing in the amino acids at positions 108 to 131 or at positions 551 to 654 of the amino acid sequence shown in SEQ ID NO: 38 that is the extracellular region of human CDH3, and has cytotoxicity against CDH3-expressing cells.Type: GrantFiled: June 19, 2012Date of Patent: September 8, 2015Assignee: PERSEUS PROTEOMICS INC.Inventors: Lilin Zhang, Katsuyuki Mitomo, Katsushi Kouda, Yoko Kayukawa
-
Publication number: 20150174198Abstract: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.Type: ApplicationFiled: November 17, 2014Publication date: June 25, 2015Inventors: Katsuyuki Mitomo, Makoto Inoue, Hitoshi Iwasaki, Mamoru Hasegawa, Eric W. Alton, Uta Griesenbach
-
Publication number: 20140328754Abstract: A radioactive metal-labeled anti-cadherin antibody which is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.Type: ApplicationFiled: June 18, 2014Publication date: November 6, 2014Applicants: Fujifilm RI Pharma Co., LTD, Perseus Proteomics Inc.Inventors: Akihiro HINO, Akio Nagano, Masahiko Watanabe, Tadasi Matsuura, Hirokazu Satoh, Fumiko Nomura, Katsuyuki Mitomo
-
Patent number: 8815211Abstract: An object of the present invention is to provide a radioactive metal anti-cadherin antibody which is highly accumulated specifically in cancer tissue. Another object is to provide a cancer therapeutic agent having high anti-cancer effect and safety and a cancer diagnostic agent. The radioactive metal-labeled anti-cadherin antibody is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.Type: GrantFiled: February 9, 2011Date of Patent: August 26, 2014Assignees: Fujifilm RI Pharma Co., Ltd., Perseus Proteomics Inc.Inventors: Akihiro Hino, Akio Nagano, Masahiko Watanabe, Tadasi Matsuura, Hirokazu Satoh, Fumiko Nomura, Katsuyuki Mitomo
-
Publication number: 20140114054Abstract: An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).Type: ApplicationFiled: May 7, 2012Publication date: April 24, 2014Applicants: UNIVERSITY OF MIYAZAKI, PERSEUS PROTEOMICS INC.Inventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Publication number: 20130317201Abstract: It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.Type: ApplicationFiled: October 28, 2011Publication date: November 28, 2013Applicant: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Keiko Katsumi, Tadashi Matsuura, Yukio Sudo, Katsuyuki Mitomo, Katsushi Kouda